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K.S. Joseph, Jeanethe Anguizola, Abby J. Jackson, and David S. Hage*
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Abstract
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Acetohexamide is a drug used to treat type II diabetes and is tightly bound to the protein human
serum albumin (HSA) in the circulation. It has been proposed that the binding of some drugs with
HSA can be affected by the non-enzymatic glycation of this protein. This study used highperformance affinity chromatography to examine the changes in acetohexamide-HSA binding that
take place as the glycation of HSA is increased. It was found in frontal analysis experiments that
the binding of acetohexamide to glycated HSA could be described by a two-site model involving
both strong and weak affinity interactions. The average association equilibrium constant (Ka) for
the high affinity interactions was in the range of 1.2–2.0 × 105 M−1 and increased in moving from
normal to HSA with glycation levels that might be found in advanced diabetes. It was found
through competition studies that acetohexamide was binding at both Sudlow sites I and II on the
glycated HSA. The Ka for acetohexamide at Sudlow site I increased by 40% in going from normal
HSA to minimally glycated HSA but then decreased back to near-normal values in going to more
highly glycated HSA. At Sudlow site II, the Ka for acetohexamide first decreased by about 40%
and then increased in going from normal HSA to minimally glycated HSA and more highly
glycated HSA. This information demonstrates the importance of conducting both frontal analysis
and site-specific binding studies in examining the effects of glycation on the interactions of a drug
with HSA.

Keywords
Acetohexamide; Human serum albumin; Glycation; Drug-protein binding; High-performance
affinity chromatography
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1. Introduction
Human serum albumin (HSA) is the most abundant protein in human plasma. It is a
globular, non-glycosylated protein that contains a single chain of 585 amino acids and has a
serum concentration of ~40 g/L [1–8]. This protein has two major binding sites for drugs
(i.e., Sudlow sites I and II) [9,10]. Sudlow site I, also known as the warfarin-azapropazone
site, binds to bulky heterocyclic compounds such as coumarin compounds, sulfonamides,
and salicylate [3,6,8,11]. Sudlow site II, or the indole-benzodiazepine site, binds aromatic
carboxylic acids and profens such as ibuprofen and ketoprofen [3,6,8,11]. HSA binds many
endogenous and exogenous compounds at these and other sites, acting as the major transport
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protein for such compounds in the circulation [8]. The binding of drugs to HSA can greatly
affect their pharmacologic properties and influence the activity of a drug by altering its free
fraction in blood [8,12].
The interactions of drugs with HSA can be affected by competition for binding sites with coadministered drugs or endogenous compounds, but they may also be affected by
modifications such as glycation [8,13]. Glycation occur when free amine groups on a protein
become non-enzymatically linked to reducing sugars such as glucose to form a Schiff base,
which can then later rearrange to form a more stable Amadori product. This process is
especially prevalent in diabetes, in which blood sugar levels are elevated. The normal level
of HSA glycation is around 6–13%, while a diabetic individual may have 20–30% of HSA
glycated in the circulation [1,2,8]. Some of the primary glycation sites on HSA have been
shown to be at or near Sudlow sites I and II, which has created interest in the possible role
these modifications may have on drug binding at these regions [2,14,15].
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Acetohexamide (Figure 1) is a sulfonylurea drug that is used in the treatment of type II, or
non-insulin dependent, diabetes [16,17]. Like many other sulfonylurea compounds,
acetohexamide binds tightly to HSA. It has been demonstrated that this binding occurs at
both Sudlow sites I and II, with equilibrium constants in the range of 4.2 × 104 to 1.3 × 105
M−1 at 37°C for normal HSA [18]. One past study conducted at pH 7.4 and 37ºC using
equilibrium gel filtration found a 44% decrease in the binding of acetohexamide to highly
glycated HSA versus normal HSA, as determined when combining similar concentrations
for the drug and protein [19]. Fluorescence quenching experiments using moderately
glycated HSA at pH 7.4 and 20ºC, plus up to a ten-fold excess of drug, suggested there was
a slight decrease in the affinity of acetohexamide for glycated HSA versus normal HSA
[20]. As these past results indicate, there is still a need for binding studies under temperature
and glycation conditions that are more typical of those expected in blood during diabetes
and for data that more clearly shows how glycation affects the interactions of acetohexamide
with HSA.
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This study will use high-performance affinity chromatography (HPAC) to examine the
binding of acetohexamide to HSA with various levels of glycation. The use of normal HSA
columns in HPAC has been shown in numerous studies to give good correlation with the
drug binding behavior noted for normal HSA in solution [21]. The benefits of using HPAC
for this research when compared to traditional methods such as equilibrium dialysis or
ultrafiltration include the good precision and reproducibility of HPAC, its small sample
requirements, and its ease of automation [21,22]. HPAC has recently been used to
characterize the binding of acetohexamide with normal HSA [18] and to examine the effects
of glycation on the binding of HSA with warfarin and L-tryptophan (i.e., site-selective
probes for Sudlow sites I and II) [23]. This current report will build on these previous
studies by first using HPAC to determine how the overall association equilibrium constants
and binding capacities of acetohexamide on HSA are affected during increasing levels of
glycation, as examined by using frontal analysis. Zonal elution experiments will then be
used to provide site-specific information on how the binding of acetohexamide at Sudlow
sites I and II is changed as the glycation of HSA is increased. The information gained from
this research should provide a better description of how acetohexamide binds to HSA during
diabetes. Such information, in turn, should aid in the future development of improved
patient treatment regimes based on acetohexamide and related drugs.
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2. Experimental
2.1 Reagents
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The acetohexamide, warfarin (≥ 97%), L-tryptophan (98%), D-(+)-glucose (99.5%), sodium
azide (>95%), HSA (essentially fatty acid free, ≥ 96%), and commercial glycated HSA (Lot
058K6087) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The Nucleosil
Si-300 (7 micron particle diameter, 300 Å pore size) was purchased from Macherey-Nagel
(Düren, Germany). Reagents used in the bicinchoninic acid (BCA) protein assay were from
Pierce (Rockford, IL, USA). The enzymatic assay kit for fructosamine was from Diazyme
Laboratories (San Diego, CA, USA). Sterile 17 × 100 mm culture tubes were purchased
from Fisher Scientific (Pittsburg, PA, USA). Slide-A-Lyzer 7K (7 kDa, MW cutoff) dialysis
cassettes with various sample volumes (0.5–3, 3–12 or 12–30 ml) were obtained from
Thermo Scientific (Rockford, IL, USA). The Econo-Pac 10 DG columns (30 × 10 ml) were
from Bio-Rad (Hercules, CA, USA). All solutions were made using water from a Nanopure
system (Barnstead, Dubuque, IA, USA) and filtered through 0.20 μm GNWP nylon
membranes from Millipore (Billerica, MA, USA).
2.2 Apparatus
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The HPLC system was from Jasco (Tokyo, Japan) and consisted of a DG-2080-53 threesolvent degasser, two PU-2080 isocratic pumps, a AS-2055 autosampler, a CO-2060 column
oven, and a UV-2075 UV/Vis detector, along with a Rheodyne Advantage PF six-port valve
(Cotati, CA, USA). The HPLC system hardware was controlled by EZChrom Elite software
v3.2.1 (Scientific Software, Pleasanton, CA, USA) via Jasco LC Net hardware. Labview 5.1
(National Instruments, Austin, TX, USA) was used to analyze the frontal analysis curves.
PeakFit 4.12 (Jandel Scientific Software, San Rafael, CA, USA) was used to determine the
central moments of peaks obtained from zonal elution experiments. Linear regression was
performed using Excel 2003 (Microsoft Corporation, Redmond, WA, USA) and non-linear
regression was carried out using DataFit (Oakdale Engineering, PA, USA).
2.3 Methods
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2.3.1 Preparation of glycated HSA and HSA columns—Diol silica was made using
Nucleosil Si-300 silica, and glycated HSA was immobilized to the diol silica by the Schiff
base method [23–26]. A control support was also made in this manner but with no protein
being added during the immobilization step. A BCA assay was performed in triplicate on
each support to determine the protein content, using glycated HSA as the standard and the
control support as the blank. Although both the Schiff base immobilization method and
glycation involve free amine residues on a protein, previous studies have determined that the
conditions typically present during these processes lead to the involvement of different
residues on HSA, with the Schiff base immobilization method predominantly using the Nterminus or a few lysines that are not present at Sudlow sites I or II (see Refs. [27–29] for
more details). Because of this difference, the prior glycation of HSA should not have
affected the ability of this protein to be immobilized by the Schiff base method or the
relative activities noted at Sudlow sites I and II for this immobilized protein. This result has
been confirmed in recent studies looking at the binding of warfarin and L-tryptophan to
glycated HSA columns that were identical to those used in this current study [23].
This report used three batches of glycated HSA, with each batch having known and different
levels of glycation. The first HSA sample was a commercial in vitro preparation (gHSA1),
as prepared under proprietary conditions by incubating a fixed concentration of D-glucose
with HSA at 37 ºC for periods of time that were no longer than a week. The second and third
samples of glycated HSA (gHSA2 and gHSA3) were prepared in a similar fashion at 37 ºC
and over four weeks using moderate or high levels of D-glucose (i.e., 15 or 30 mM), as
J Chromatogr B Analyt Technol Biomed Life Sci. Author manuscript; available in PMC 2011 October 15.
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described previously [23]. The resulting protein solutions were stored at −80 °C. A portion
of each solution was lyophilized and the resulting protein sample was stored at −80 °C until
use. A commercial fructosamine assay designed for work with serum samples was modified
to determine the glycation levels in each HSA sample, as described in Ref. [23].
2.3.2. Chromatographic methods—After each type of glycated HSA had been
immobilized, the resulting supports were downward slurry-packed into separate 2.0 cm × 2.1
mm I.D. columns at 3500 psi (24 MPa) using pH 7.4, 0.067 M potassium phosphate buffer
as the packing solution. The corresponding control supports were packed into separate
columns under the same conditions. These columns were stored at 4 °C in the packing
solution and used over a period of one year and fewer than 500 sample applications. Similar
columns containing normal HSA have been found in previous work to have good stability
for drug-protein binding studies under such conditions [30].
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The acetohexamide, R-warfarin, and L-tryptophan solutions were made in pH 7.4, 0.067 M
potassium phosphate buffer. This buffer was also used as the application and elution buffer
in the chromatographic studies. All solutions were filtered through a 0.2 μM nylon filter and
degassed for 10–15 min prior to use. A flow rate of 0.5 ml/min was used for both the frontal
analysis and zonal elution studies. This flow rate has been shown in previous studies to give
reproducible retention factors and binding capacities for drug binding studies conducted on
similar columns containing normal HSA [31,32]. All of the chromatographic studies were
performed at 37 °C.
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In the frontal analysis experiments, the column was first equilibrated with pH 7.4, 0.067 M
potassium phosphate buffer and then switched to the desired sample solution using an
automated six-port valve. Once the analyte had saturated the column and produced a
breakthrough curve, the valve was switched and pH 7.4, 0.067 M phosphate buffer was used
to elute the remaining analyte from the column. The analyte solutions contained
acetohexamide at concentrations that ranged from 1–1000 μM. Although the pKa of
sulfonylurea drugs like acetohexamide range from 5.2–6.2, even the solutions containing the
highest concentration of acetohexamide gave less than a 0.05 change in pH for the pH 7.4
buffer, and the pH of this solution was found to vary by less than 0.05 units over the course
of this study. The elution of acetohexamide was monitored at 248 nm for the 1–7.5 μM
solutions and at 315 nm for the 10–1000 μM solutions (note: the detection wavelength was
changed to keep the absorbance values within a linear range of response as the concentration
was increased). All experiments were performed in triplicate and the resulting breakthrough
curves were analyzed using the equal areas method [21]. Non-specific binding was corrected
by subtracting the results for the control column from the results for each glycated HSA
column.
The zonal elution competition studies were performed by using R-warfarin as a probe for
Sudlow site I and L-tryptophan as a probe for Sudlow site II [9,10,23]. Recent studies have
shown that these probe compounds are specific for these sites even when using HSA that has
been glycated at levels like those used in this current study [23]. Concentrations of
acetohexamide ranging from 1–20 μM were placed in the mobile phase for the competition
experiments. The injected samples consisted of 20 μL of 5 μM R-warfarin or L-tryptophan,
conditions which have been shown to represent linear elution conditions for similar HSA
columns [33,34]. The elution of R-warfarin or L-tryptophan was monitored at 308 or 280
nm, respectively. Injections consisting of 20 μL of 20 μM sodium nitrate (i.e., a non-retained
solute) were made under the same conditions to determine the column void time, with the
elution of sodium nitrate being monitored at 205 nm. The resulting peaks were fit to an
exponentially-modified Gaussian curve to find their central moments for retention time or
void time measurements.
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3. Results and Discussion
3.1 Preparation of Glycated HSA
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Previous studies have compared the interactions of acetohexamide to HSA versus glycated
HSA by examining either changes in the binding capacities of these proteins or the
differences in their apparent binding constants [19,20]. However, these past studies did not
compare the binding of acetohexamide with HSA having various levels of glycation and did
not consider how the binding of this drug to specific sites on HSA may change with
glycation. These studies also conducted binding studies at lower temperatures than are
present in the body [20] or used higher glucose concentrations for HSA glycation than are
found in the body during diabetes [19]. These limitations were overcome in this present
study by conducting all interaction studies at 37ºC and by using HSA that had undergone
various known levels of glycation under conditions similar to those found in serum during
diabetes.

NIH-PA Author Manuscript

There were three preparations of in vitro glycated HSA that were utilized in this study. The
first preparation (referred to as gHSA1, and obtained from a commercial source) had a
relatively low level of glycation of 1.31 (± 0.05) mol hexose/mol HSA. This preparation was
used to represent minimally glycated HSA, as might be found during pre-diabetes or early
state diabetes. The second sample, gHSA2, had a glycation level of 2.34 (± 0.13) mol
hexose/mol HSA and was made using glucose conditions typical of those seen in many
patients with diabetes [35]. The third sample, gHSA3, contained 3.35 (± 0.14) mol hexose/
mol HSA and was used to represent a case of uncontrolled, advanced diabetes. After these
various preparations had been immobilized, their supports were found to have protein
contents of 29 (± 4), 47 (± 8), and 40 (± 3) mg protein/g silica, respectively (i.e., ~440–710
nmol HSA/g silica). These protein levels were comparable to those reported for normal HSA
supports made by the same immobilization method [26].
3.2. Frontal analysis studies
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Breakthrough curves were collected for acetohexamide on each glycated HSA column. An
example of such an experiment is given in Figure 2(a), as acquired for the gHSA2 column.
This data was first analyzed by using a double-reciprocal plot of 1/mLapp versus 1/
[Acetohexamide], as prepared according to Eqn. (1) (see Table 1 for a list of all equations
used in this report). An example of this type of plot is provided in Figure 3. Deviations from
a linear response in such a plot were noted for all of the glycated HSA columns, indicating
that more than one type of binding site for acetohexamide was present (e.g., see behavior
predicted for a two-site model by Eqns. (2)–(3) in Table 1). The same type of behavior has
been reported in previous studies examining the binding of acetohexamide to columns
containing normal HSA [18]. One advantage of using frontal analysis for this type of
analysis was that it allowed the association equilibrium constants and binding capacities of
the column to be measured independently from one another [21,22], thus making it possible
to obtain values for the association equilibrium constants that were not affected by moderate
column-to-column variations in the amount of immobilized HSA that was present.
The linear range in the double-reciprocal plots was used with the behavior predicted by Eqn.
(4) at low analyte concentrations to provide an initial estimate of the association equilibrium
constant for the highest affinity sites of acetohexamide in each column. This linear range
occurred at acetohexamide concentrations below 10 μM and gave correlation coefficients of
0.998–0.999 (n = 6–7) over this range. The estimated association equilibrium constants
obtained by this approach for the high affinity binding regions of acetohexamide were as
follows: gHSA1, 2.0 (± 0.2) ×105 M−1; gHSA2, 2.0 (± 0.2) × 105 M−1; and gHSA3, 1.9 (±
0.1) × 105 M−1. Use of the same approach with acetohexamide on a normal HSA column
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has given a previous estimate of 2.0 (± 0.2) ×105 M−1 for these high affinity interactions
[18]. Thus, at first glance, the interactions of acetohexamide did not appear to have any
significant change at these high affinity sites as the extent of glycation for HSA was varied.
A more detailed analysis was conducted by fitting the frontal analysis data to a two-site
model by using Eqn. (3). This type of fit has been shown in the past to give the best
description for the binding of acetohexamide to columns containing normal HSA, involving
both a group of low affinity interactions and a set of high affinity sites [18]. This same type
of model was found to give a good fit for the results obtained on each glycated HSA
column, with correlation coefficients of 0.998–0.999 (n = 15). Only random variations in the
data about the best-fit lines were observed in these plots, along with a small sum of the
square of the residuals (range, 2.0 × 10−18 to 4.9 × 10−18). In comparison, the use of a
single-site model with the same data gave non-random variations of the residuals about the
best-fit line, correlation coefficients of 0.979–0.990, and a larger sum of the square of the
residuals (3.5 × 10−17 to 8.4 × 10−17).
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Table 2 summarizes the association equilibrium constants and amount of each class of
binding sites that were noted for the glycated HSA columns when using the two-site model.
The association equilibrium constant (Ka) values for the high affinity interactions gave good
general agreement with the values estimated from the linear regions of plots made according
to Eqn. (4), but a gradual increase in these values with the level of glycation was also
observed. This increase occurred in going from normal HSA (i.e., using a value obtained
from Ref. [18]) or gHSA1, with values of 1.2–1.3 × 105 M−1, to the gHSA2 and gHSA3
samples, which both gave a Ka value of 2.0 × 105 M−1 for their high affinity sites (i.e., a 1.5to 1.7-fold increase). This increase (e.g., as measured between normal HSA and gHSA1
versus gHSA3) was significant at the 95% confidence level. These results agreed with data
obtained using acetohexamide and soluble gHSA3 or normal HSA in ultrafiltration studies
(data not shown). The amount of these high affinity regions were all in the general range of
1.5–2.4 × 10−8 mol, which represented specific activities of 0.8–1.3 for acetohexamide.
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The average association equilibrium constants estimated for the lower affinity sites
increased from 0.35 × 103 M−1 to 1.4–11 × 103 M−1 in going from normal HSA to the
glycated HSA samples. However, the estimated specific activities of these lower affinity
sites decreased from 5.2 to 1.1–1.6 for the same protein preparations. This combined effect
resulted in an increase in the product Ka2 n2 (i.e., Ka2 multiplied by the specific activity for
the low affinity sites) from approximately 1.8 × 103 M−1 for normal HSA and gHSA1 to
6.6–12.1 × 103 for gHSA2 and gHSA3, a change that was significant at the 95% confidence
level. Such a result suggests that a small amount of glycation (e.g., as in gHSA1) did not
have any appreciable effect on these lower affinity interactions, while a greater degree of
glycation (e.g., as in gHSA2 and gHSA3) did raise the extent of lower affinity interactions
for acetohexamide with HSA.
3.3 Competition studies at Sudlow site I
Zonal elution competition studies were next performed to examine binding of
acetohexamide at Sudlow site I as the level of glycation for HSA was varied. These
experiments were carried out using R-warfarin as a site-selective probe. An example of such
a study is given in Figure 2(b). When a plot of 1/k vs. [Acetohexamide] was made for
injections of R-warfarin, a linear response was obtained for all glycated HSA columns that
were tested. These plots gave correlation coefficients of 0.970–0.992 (n = 6) and only
random deviations in the data about the best-fit lines. In addition, the best-fit intercepts
agreed within ± 2 S.D. with the actual intercepts measured in the absence of any
acetohexamide in the mobile phase. These results indicated that there was direct competition
between R-warfarin and acetohexamide on the glycated HSA columns, indicating that
J Chromatogr B Analyt Technol Biomed Life Sci. Author manuscript; available in PMC 2011 October 15.
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acetohexamide was binding at Sudlow site I. The same type of behavior has been noted for
acetohexamide on columns containing normal HSA [18].

NIH-PA Author Manuscript

The association equilibrium constant for acetohexamide at Sudlow site I was found by
taking the ratio of the slope to the intercept for plots of 1/k versus [Acetohexamide] when
injecting R-warfarin as a probe, as indicated by Eqn. (5) (Note: the use of this approach and
equation to measure an association equilibrium constant at a given binding site provides a
value that is independent of the amount of immobilized protein and of column-to-column
variations in this protein content [21,22]). The results that were obtained from these plots are
summarized in Table 3. In going from normal HSA to gHSA1, there was about a 40%
increase in binding affinity for acetohexamide at Sudlow site I. This increase was
statistically significant at the 95% confidence level. This was followed by a similar,
statistically significant decrease for gHSA2 and gHSA3 to values that were comparable to
those for normal HSA (i.e., values only 3–10% below Ka for normal HSA and within of ± 1
S.D. of this value). This trend is believed to be linked to differences in the glycation patterns
of these samples as a result of differences in their preparation conditions and the resulting
modifications and/or local alterations in the structure of HSA that occurred at or near
Sudlow site I as a result of these modifications in the early, intermediate and advanced
stages of glycation.
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It was possible from plots prepared according to Eqn. (5) to also determine how the specific
activity of Sudlow site I changed for acetohexamide as the level of glycation for HSA was
increased. This was done by using the intercept of such a plot along with the previouslymeasured Ka values for R-warfarin with each type of glycated HSA used in this study [23]
and the known protein content of the columns. No significant change in specific activity was
seen for acetohexamide at Sudlow site in going from normal HSA to the gHSA1 or gHSA2
columns. However, up to a 30% decrease in specific activity may have been present when
comparing gHSA3 to normal HSA or gHSA1 (i.e., changes significant at the 90% and 95%
confidence levels, respectively).
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Previous binding studies did not find any significant changes in the affinity or specific
activity for R-warfarin at Sudlow site I in going from normal HSA to glycated HSA when
using columns identical to those employed in this current report [23]. The different behavior
seen here for acetohexamide versus the earlier results for R-warfarin indicates that the
effects of glycation-related modifications at or near Sudlow site I can differ from one drug
or solute. Work with additional pharmaceutical agents, including other sulfonylurea
compounds, is in progress to further determine the extent to which these interactions can
vary between structurally-related drugs that bind to this region of HSA. Such differences
have already been noted in competition experiments that have been conducted with
tolbutamide at Sudlow site I, which gave a 1.2- to 1.3-fold increase in Ka for this drug in
going from the normal HSA column to all of the glycated HSA columns that were used in
this current report [36].
3.4 Competition studies at Sudlow site II
Competition studies based on zonal elution experiments were also carried out for
acetohexamide at Sudlow site II for the various samples of glycated HSA that were
examined in this report. These experiments were conducted by using L-tryptophan as a siteselective probe. Plots of 1/k vs. [Acetohexamide] that were generated during the injection of
L-tryptophan gave a linear response for each glycated HSA column. These plots had
correlation coefficients in the range of 0.991–0.996 (n = 5 or 6), along with only random
deviations in the data about the best-fit lines. The best-fit intercepts also agreed within ± 2
S.D. with the actual intercepts noted in the absence of any acetohexamide in the mobile
phase. From these results it was determined that there was direct competition between LJ Chromatogr B Analyt Technol Biomed Life Sci. Author manuscript; available in PMC 2011 October 15.
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tryptophan and acetohexamide on the glycated HSA columns, as has also been noted on
columns containing normal HSA [18]. These data indicated that acetohexamide was binding
at Sudlow site II on the various samples of glycated HSA that were tested.
The association equilibrium constants that were calculated for acetohexamide at Sudlow site
II are given in Table 3. The pattern noted here was just the opposite of the trend seen in the
previous section for acetohexamide at Sudlow site I. For instance, in going from normal
HSA to gHSA1, there was a 40% decrease in binding affinity for acetohexamide (significant
at the 95% confidence level), followed by an increase back to values for gHSA2 and gHSA3
that were only 8–15% below those for normal HSA. This trend is again believed to be linked
to changes in the types of glycated-related modifications that occur at or near Sudlow site II
as a result of different stages of glycation. It is interesting to note that the different changes
seen for acetohexamide at Sudlow sites I and II produced a net average binding strength at
these high affinity regions that was comparable to that for the other HSA samples. This
explains why only smaller differences were noted in the frontal analysis data when
comparing these samples.
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Data from the competition studies were used to compare the specific activities for
acetohexamide at Sudlow site II on each of the glycated HSA columns. This was carried out
using the same approach as described in the previous section but now used the competition
data and the known protein content of each column along with previously-measured values
of Ka for L-tryptophan on the glycated HSA samples that were used in this study [23]. In
this case, no significant change at either the 90% or 95% confidence level was seen in the
specific activity of Sudlow site II for acetohexamide when comparing any of the glycated
HSA columns or versus the specific activity expected for normal HSA.
Prior frontal analysis experiments have indicated that there is almost a five- to six-fold
change in affinity for L-tryptophan at Sudlow site II in going from normal HSA to any of the
glycated HSA samples used in this current report [23]. As was noted in the last section for
Sudlow site I, this difference from the results seen here for acetohexamide indicate that the
effects of glycation-related modifications can vary between solutes that bind to the same
region of HSA. For example, competition experiments using tolbutamide have found that
there is a 1.1-to 1.4-fold increase in Ka for this drug at Sudlow site II in going from normal
HSA to any of the glycated HSA samples that were tested in this current report [36].

4. Conclusions

NIH-PA Author Manuscript

These studies used high-performance affinity chromatography as a tool to see how the
binding of acetohexamide with HSA changes as the level of glycation for this protein is
increased. As has been found for normal HSA [18], frontal analysis indicated that the
binding of acetohexamide to glycated HSA followed a two site model that included a group
of high affinity sites and a set of lower affinity interactions. The Ka values for the high
affinity interactions were in the general range of 1.2–2.0 × 105 M−1 and appeared to increase
in going from normal or minimally glycated HSA to more highly glycated HSA. An increase
in the extent of lower affinity interactions were also noted in going from normal or
minimally glycated HSA to the more highly glycated samples of HSA.
Competition studies indicated that the association equilibrium constant of acetohexamide at
Sudlow site I initially increased in going from normal HSA to minimally glycated HSA. The
value of Ka then decreased in going to more highly glycated HSA. Different behavior was
seen at Sudlow site II, in which the Ka for acetohexamide first decreased and then increased
in going from normal HSA to minimally glycated HSA and more highly glycated HSA.
Such information demonstrates the importance of conducting both frontal analysis and site-
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specific binding studies in examining the effects of glycation on the interactions of a drug
with HSA. The results noted in this current study may have clinical relevance in that
sulfonylurea drugs such as acetohexamide are often used to help patients with poor glycemic
control in diabetes. However, obtaining normal blood sugar levels in diabetic patients can be
elusive and difficult to routinely accomplish in the long term [35].
The results on this study suggest that there may be difference in the binding of drugs such as
acetohexamide to HSA as the levels of glucose in blood are normalized in these patients
(i.e., which would tend to gradually lower glycation levels) or as the diabetes progresses
(which would tend to increase glycation). Binding experiments similar to those described in
this report are now being conducted with in vivo glycated HSA to further investigate the
effects of changes in glycation.

NIH-PA Author Manuscript

The differences in binding seen in this report in the competition studies for the various
preparations of HSA are thought to be linked to changes in the preparation conditions and in
the glycated-related modifications that occur at or near Sudlow sites I and II in the presence
of various stages of glycation. The belief that these variations are related to glycation
patterns rather than immobilization effects is supported by the fact that the same columns
have been found with other solutes to have either no changes in binding affinity (e.g., as
noted for warfarin at Sudlow site I) [23] or a more consistent change in binding strength as
the level of glycation is increased (e.g., as seen for L-tryptophan at Sudlow site II [23] and
for tolbutamide at both Sudlow sites I or II [36]). Future work with a new method for noncovalently entrapping HSA will be used to further investigate these trends [37]. Structural
studies using tools from quantitative proteomics are also being carried out to determine
which residues in HSA may lead to these changes in binding properties upon glycation (e.g.,
see Ref. [28]). The data that can be obtained through such research should result in a better
understanding of how glycation can change the interactions of drugs such as acetohexamide
to HSA during diabetes. This information, in turn, should aid in the later development of
better patient treatments based on acetohexamide and related drugs.
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Figure 1.

Structure of acetohexamide.
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Figure 2.
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Examples of (a) breakthrough curves for acetohexamide and (b) zonal elution competition
studies for injections of R-warfarin in the presence of acetohexamide. These results were
obtained on the gHSA2 column. The concentrations of acetohexamide in (a) were as follows
(from left-to-right): 1000, 500, 300, 100 and 50 μM. In (b) using 20 μL of 5 μM R-warfarin
was injected in the presence of the following concentrations of acetohexamide in the mobile
phase (from top-to-bottom): 20, 15, 10, 5 and 1 μM.
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Figure 3.

A double-reciprocal plot for the binding of acetohexamide to a column containing a
preparation of gHSA1. The best-fit line obtained when fitting the linear region of this plot
(i.e., the data at 1–10 μM acetohexamide) to Eqn. (4) was as follows: y = 360 (± 10) x + [7.4
(± 0.5) × 107], r = 0.998, n = 7. The error bars represent a range of ± 1 SD.
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Figure 4.

A plot of mLapp versus [Acetohexamide] for the gHSA1 column, as analyzed according to
Eqn. (3) and using a two-site model. The best-fit values that were obtained for the
association equilibrium constants and binding capacities are summarized in Table 3.
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Figure 5.

Change in the retention factor for (a) R-warfarin or (b) L-tryptophan as the mobile phase
concentration of acetohexamide was varied on a gHSA1 column, as analyzed according to
Eqn. (5). The best-fit line in (a) was y = 1100 (± 100) x + 0.018 (± 0.001), r = 0.991, n = 6.
The best-fit line in (b) was y = [2.1 (± 0.1) × 104] x + 0.27 (± 0.02), r = 0.991, n = 6. The
error bars represent a range of ± 1 SD.
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KaA, association equilibrium constants for the competing agent and probe, respectively, at their site of competition; VM, column void volume.

affinity site (e.g., Ka2) versus the highest affinity site, where β2 = Ka2/Ka1 and 0 < Ka2 < Ka1; tR, measured retention time; tM, column void time; k, retention factor, where k = (tR − tM)/tM; KaI and

concentration of applied analyte; α1, fraction of all binding regions that make up the high affinity binding sites (i.e., α1 = mL1,tot/mLtot); β2, ratio of the association equilibrium constant for any lower

Abbreviations and terms: Ka, association equilibrium constant; mL, moles of binding sites; mLapp, apparent moles of analyte required to reach the central position of the breakthrough curve at a given

a

mLapp

1

1
1
1
=
+
mLapp
(K m A ) m
a L
L

Predicted responsea

α1 + β22 − α1β22
1
1
lim
=
+
mLapp
mLtot (α1 + β2 − α1β2) K a1 A
mLtot (α1 + β2 − α1β2)2
A →0

Direct competition of A with agent I in the mobile phase for a single set of binding sites on
L

Zonal Elution

Linear response to a two-site model at low concentrations of A

Two-site binding of A with L

Frontal analysis

Binding models and equations used in frontal analysis and zonal elution studies [21,22]
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1.2 (± 0.2)
2.0 (± 0.6)
2.0 (± 0.3)

gHSA1

gHSA2

gHSA3

1.5 (± 0.1)

1.8 (± 0.3)

1.7 (± 0.1)

2.4 (± 0.1)

0.80 (± 0.09)

0.80 (± 0.20)

1.3 (± 0.2)

1.3 (± 0.1)

Specific activity (mol/mol HSA)

High affinity sites
mL1 (× 10−8 mol)

4.1 (± 0.7)

11 (± 3)

1.4 (± 0.8)

0.35 (± 0.03)

Ka2 (× 103 M−1)

3.0 (± 0.1)

2.4 (± 0.3)

1.7 (± 0.4)

9.3 (± 5.5)

1.6 (± 0.5)

1.1 (± 0.2)

1.3 (± 0.3)

5.2 (± 3.1)

Specific activity (mol/mol HSA)

Low affinity sites
mL2 (× 10−8 mol)

The results for normal HSA were obtained from Ref. [18] and were acquired using immobilization and chromatographic conditions identical to those used in this current study for glycated HSA.

b

The values in parenthesis represent ± 1 S.D. These values were determined by using error propagation and the standard deviations of the slopes and intercepts that were obtained from best-fit lines
generated according to Eqn. (3).

a

1.3 (± 0.2)

HSAb

Type of column

Ka1 (× 105 M−1)

Binding parameters obtained for acetohexamide with glycated HSA by frontal analysis and using a two-site modela
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5.9 (± 0.5)
3.8 (± 0.3)
4.1 (± 0.6)

gHSA1

gHSA2

gHSA3

12 (± 1)

11 (± 1)

7.9 (± 0.7)

13 (± 1)

Ka, Sudlow Site II (× 104 M−1)

The results for normal HSA were obtained from Ref. [18] and were acquired using immobilization and chromatographic conditions identical to those used in this current study for glycated HSA.

b

The values in parenthesis represent ± 1 S.D. These values were determined by using error propagation and the standard deviations of the slopes and intercepts that were obtained from best-fit lines generated
according to Eqn. (5).

4.2 (± 0.4)

Ka, Sudlow site I (× 104 M−1)

HSAb

Type of column

Association equilibrium constants (Ka) obtained at Sudlow sites I and II for acetohexamide with glycated HSAa
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